DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/lks69g/bosatria) has announced the addition of the "Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023" report to their offering.
GSK's Bosatria (mepolizumab) is a humanized mAb targeting IL-5, a cytokine that regulates the activation of eosinophils. It was originally developed for the treatment of hypereosinophilic syndrome, but GSK withdrew its authorization application after the CHMP determined that the data were insufficient to conclude whether there is a positive benefit-risk balance for Bosatria in asthma (GSK, press release, July 29, 2009). GSK boasts multibillion dollar sales for its blockbuster, Advair/Seretide, but Bosatria is not expected to reach this status, since it will only be used in a limited number of refractory patients.
- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Bosatria including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Bosatria for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Unmet Need and Opportunity
7 Pipeline Assessment
8 Bosatria (Mepolizumab)
For more information visit http://www.researchandmarkets.com/research/lks69g/bosatria